AMAG Pharma (AMAG) Tops Q1 EPS by 29c; Boosts FY15 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts AMAG Hot Sheet
Price: $13.75 --0%
Financial Fact:
Diluted (in shares): 42.11M
Today's EPS Names:
JBLU, SICP, OMID, More
Financial Fact:
Diluted (in shares): 42.11M
Today's EPS Names:
JBLU, SICP, OMID, More
Join SI Premium – FREE
AMAG Pharma (NASDAQ: AMAG) reported Q1 EPS of $1.17, $0.29 better than the analyst estimate of $0.88. Revenue for the quarter came in at $89.5 million versus the consensus estimate of $84.66 million.
AMAG Pharma sees FY2015 revenue of $395-430 million, versus prior guidance of $380-420 million and the consensus of $397.6 million.
For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
- Chicopee Bancorp (CBNK) Misses Q3 EPS by 3c
- Noble Corp (NE) Misses Q3 EPS by 81c; Offers Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
